Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Nina Mitchell"'
Publikováno v:
Journal of Magnetic Resonance Imaging. 56:1559-1568
Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer
Autor:
Fan Yang, Wing Yen Wong, Stephen J. Zoog, Hassibullah Akeefe, Elli Koziol, Christian Vettermann, Jennifer Holcomb, Annie Clark, Kevin Hammon, Joshua Henshaw, Nina Mitchell, Kathryn Patton, Krystal Sandza, Benjamin Kim
Publikováno v:
Gene Therapy. 29:94-105
Adeno-associated virus (AAV)-based gene therapy vectors are replication-incompetent and thus pose minimal risk for horizontal transmission or release into the environment. In studies with AAV5-FVIII-SQ (valoctocogene roxaparvovec), an investigational
Autor:
Nina Mitchell, Wing Yen Wong, Federico Mingozzi, M. Benjamin Hock, Kelly Lau, Romain Hardet, Mingjin Li, Brian Long, Klaudia Kuranda, Stephen J. Zoog, Gregory M. Hayes, Becky Schweighardt, Christian Vettermann, Philippe Veron
Publikováno v:
Molecular Therapy
Molecular Therapy, Cell Press, 2021, 29 (2), pp.597-610. ⟨10.1016/j.ymthe.2020.12.008⟩
Molecular Therapy, 2021, 29 (2), pp.597-610. ⟨10.1016/j.ymthe.2020.12.008⟩
Molecular Therapy, Cell Press, 2021, 29 (2), pp.597-610. ⟨10.1016/j.ymthe.2020.12.008⟩
Molecular Therapy, 2021, 29 (2), pp.597-610. ⟨10.1016/j.ymthe.2020.12.008⟩
Evaluation of immune responses to adeno-associated virus (AAV)-mediated gene therapies prior to and following dose administration plays a key role in determining therapeutic safety and efficacy. This report describes up to 3 years of immunogenicity d
Autor:
Julia Smith, Alexandra R. Roberts, Charles Peterfy, Paul P. Tak, Philip G. Conaghan, Nina Mitchell, Robert L. Janiczek, Mario Berkowitz, Didier Saurigny, Elena Fisheleva, Katherine Davy, David Inman, Mark C. Genovese, Jatin Patel, Russell Williamson, Anubha Gupta, Mark Layton
Publikováno v:
The Lancet Rheumatology. 2:e666-e676
Summary Background Otilimab is a human monoclonal antibody that inhibits granulocyte–macrophage colony-stimulating factor (GM-CSF), a driver in many immune-mediated inflammatory conditions. We evaluated the effect of otilimab on the GM-CSF–chemok
Autor:
Tara M Robinson, Savita Rangarajan, K. John Pasi, Michael Laffan, Emily Symington, Will Lester, Bella Madan, Wing Yen Wong, Glenn F. Pierce, Xinqun Yang, Benjamin Kim, Nina Mitchell
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 27(6)
Introduction Valoctocogene roxaparvovec is an investigational AAV5-based factor VIII (FVIII) gene therapy that has demonstrated sustained clinical benefit in people with severe haemophilia A. Aim To report safety, tolerability, efficacy, and quality
Autor:
Sylvia Fong, Bridget Yates, Choong-Ryoul Sihn, Aras Mattis, Nina Mitchell, Su Liu, Chris Russell, Benjamin Kim, Adebayo Lawal, Savita Rangarajan, Will Lester, Stuart Bunting, Glenn Pierce, K.Joh Pasi, Wing Yen Wong
Publikováno v:
Journal of Hepatology. 77:S404
Autor:
Sylvia Fong, Bridget Yates, Choong-Ryoul Sihn, Aras N. Mattis, Nina Mitchell, Su Liu, Chris B. Russell, Benjamin Kim, Adebayo Lawal, Savita Rangarajan, Will Lester, Stuart Bunting, Glenn F. Pierce, K. John Pasi, Wing Yen Wong
Publikováno v:
Nature medicine. 28(4)
Factor VIII gene transfer with a single intravenous infusion of valoctocogene roxaparvovec (AAV5-hFVIII-SQ) has demonstrated clinical benefits lasting 5 years to date in people with severe hemophilia A. Molecular mechanisms underlying sustained AAV5-
Autor:
Jesus A Simón-Campos, Christopher D. Buckley, Didier Saurigny, Elena Fisheleva, Anubha Gupta, Mark Layton, Jatin Patel, Carol Hawkes, Paul P. Tak, Russell Williamson, David Inman, Katherine Davy, Brandon D. Becker, Nina Mitchell, Vyacheslav Zhdan
Background The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ae4e653671eae7669ab3ba14c9131b
https://ora.ox.ac.uk/objects/uuid:5d0481f9-fb31-4f3d-b5f6-14b97e04e42e
https://ora.ox.ac.uk/objects/uuid:5d0481f9-fb31-4f3d-b5f6-14b97e04e42e
Autor:
Chris B. Russell, Nina Mitchell, K. John Pasi, Savita Rangarajan, Wing Yen Wong, Michael Laffan, Will Lester, Bella Madan, Glenn F. Pierce, Emily Symington, Mingjin Li
BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHOD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fb2f488cde0f386819c674b197bcaa
http://hdl.handle.net/10044/1/75763
http://hdl.handle.net/10044/1/75763
Autor:
Didier Saurigny, Deven Chauhan, Russell Williamson, Carol Hawkes, Brandon D. Becker, Paul P. Tak, David Inman, Katherine Davy, Christopher D. Buckley, Jesus Simon Campos, Jatin Patel, Mark Layton, Nina Mitchell, Vyacheslav Zhdan
Publikováno v:
Oral Presentations.
Background GSK3196165 is a human mAb that inhibits GM-CSF, a key driver in a broad range of immune-mediated conditions (Hamilton, 2016). In trials of patients with RA, inhibition of GM-CSF signaling has resulted in clinical benefit. GM-CSF is not onl